|View printer-friendly version|
|June 06, 2007 1:47 p.m.|
|Copaxone® Pre-Filled Syringe Can Now Be Stored For Up To One Month At Room Temperature|
Approved In The U.S. And In Europe,Extended Storage Provides Enhanced Convenience for Relapsing-Remitting Multiple Sclerosis (RRMS) Patients
Paris, France and Jerusalem, Israel, June 6, 2007 - Teva Pharmaceutical Industries, Ltd. and sanofi-aventis announced today that the application for up to one month room temperature storage of COPAXONE® (glatiramer acetate injection) pre-filled syringe has been approved by the U.S. Food and Drug Administration (FDA) and in Europe under the Mutual Recognition Procedure (MRP). With this supplemental amendment, COPAXONE® may now be stored by patients at room temperature for up to one month.